Media ReleasesInnate Immunotherapeutics

View All Innate Immunotherapeutics News

Innate Immunotherapeutics, American Academy of Neurologists Posters and Key Opinion Leader Meeting Presentation

Innate Immunotherapeutics Limited (ASX Code:IIL), together with a number of Australian, Canadian, and Danish scientific collaborators presented five posters at last week’s American Academy of Neurology (AAN) Annual Meeting held in Boston.

In parallel with the AAN meeting the Company hosted a meeting of clinical and scientific key opinion leaders in the field of progressive multiple sclerosis to provide an update on the MIS416 clinical development programme and latest insights into the drug's mechanism of action. This presentation is attached.

For further information please download PDF attached:
Download this document

Are you a 708 sophisticated investor?

If you are a sophisticated investor as defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

We can alert you to wholesale investment opportunities not available to regular investors.

Please subscribe if you would like to be alerted to these types of opportunities.